DAXOR CORP - 10-Q Filing Summary
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended September 30, 2005. DAXOR Corporation is a medical device manufacturer focused on the Blood Volume Analyzer (BVA-100) and offers biotech services, including cryobanking of blood and semen, through its subsidiary, Scientific Medical Systems Corp. The company also maintains a significant investment portfolio in utility stocks.
Key Financial Metrics
| Metric | Three Months Ended Sep 30, 2005 | Nine Months Ended Sep 30, 2005 |
|---|---|---|
| Total Revenues | $340,795 | $897,367 |
| Net Income (Loss) | $995,821 | $(446,954) |
| Operating Loss | $(1,281,720) | $(3,728,977) |
| Other Income (Investments) | $2,277,541 | $3,282,023 |
| Cash and Equivalents | $2,207,288 | N/A |
| Total Assets | $63,791,318 | N/A |
| Total Liabilities | $21,836,590 | N/A |
| Stockholders' Equity | $41,954,728 | N/A |
Debt and Liquidity: The company holds $7,801,290 in loans payable (short-term), secured by marketable securities. This includes a $1.5 million bank note and $6.3 million in margin debt. Cash flow from operating activities was negative $(1,430,650) for the nine-month period, while investing activities provided $3,110,953, largely due to proceeds from broker loans.
Material Changes vs. Prior Period
- Profitability Shift: The company reported a net income of $995,821 for the three months ended September 30, 2005, compared to a net loss of $(45,519) in the same period in 2004. This turnaround was driven by investment income rather than operations.
- Investment Gains: Gains on the sale of securities increased to $1,321,733 (Q3 2005) from $321,232 (Q3 2004). Dividend income rose to $969,064 from $516,525.
- Operating Performance: Operating revenues increased 17% to $340,795 in Q3 2005, primarily due to increased sales of blood volume kits. However, operating expenses rose 44% to $1.62 million, resulting in a wider operating loss of $(1.28) million compared to $(838,562) in 2004.
- Restatements: 2004 financial figures were restated to reflect a change in accounting principle regarding deferred revenue on long-term storage fees.
Outlook, Risks, and Management Commentary
- Medicare Reimbursement: A critical factor affecting sales is a delay in Medicare reimbursement for the radiopharmaceutical kits. A reimbursement number was issued in July 2005 but will not take effect until January 2006. Management notes this error hindered hospital marketing in 2004 and early 2005.
- Investment Portfolio: The investment portfolio is a critical source of supplemental income, offsetting operating losses. The portfolio holds $60.6 million in securities with a net unrealized gain of $35.6 million. Management does not intend to liquidate holdings to utilize net operating loss carryovers.
- Marketing Initiatives: The company is expanding its sales force (13 salesmen, 4 support) and marketing the BVA-100. They recently publicized a case study of successful pregnancies from cryopreserved semen stored for 21 and 28 years.
- Risks: Risks include the company's continued operating losses, reliance on investment income, and the potential for utility stocks to be called away at prices higher than cost, reducing future yield. Two bonds in the portfolio are in default, valued at zero.
Investor Verification Checklist
- Operating Viability: Verify if the January 2006 Medicare reimbursement implementation will materially increase equipment and kit sales to cover the $3.7 million operating loss incurred in the first nine months.
- Debt Covenants: Review the terms of the $7.8 million in secured loans and margin debt to ensure the company remains in compliance given the volatility of the utility stock portfolio.
- Investment Sustainability: Assess the sustainability of the investment strategy, specifically the reliance on dividend income and short-selling strategies to fund operations.
- Defaulted Assets: Confirm the status of the two defaulted bonds (cost $48,255) and the potential for recovery or write-off.
- Revenue Recognition: Monitor the impact of the October 2005 change in billing procedures for cryobanking services on future revenue recognition patterns.